Juno Therapeutics, Inc.

Operating margin

−436.3%

Net margin

−425.3%

Return on equity

−7.9%

Return on assets

−5.7%

Return on capital (ROCE)

−6.9%

Liabilities / assets

—

Debt / equity

—

Book value / share

$9.88

Revenue growth (YoY)

97.7%

Net income growth (YoY)

—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Accruals / assets

10.0%moderate

Piotroski F-Score

2/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Phase 2Recruitingreadout ~2027-06-30
  Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
• Phase 1Recruitingreadout ~2027-07-15
  A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
• Phase 1/2Recruitingreadout ~2027-11-26
  Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
• Phase 3Recruitingreadout ~2027-12-30
  A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
• Phase 2Recruitingreadout ~2028-01-09
  A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
• Phase 2Recruitingreadout ~2028-05-17
  A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
• Phase 1Recruitingreadout ~2028-08-01
  A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
• Phase 1Recruitingreadout ~2028-08-29
  A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

• Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMar 6, 2018
• Director / officer changeFeb 1, 2018
• Entered a material agreementJan 22, 2018
• Other material eventJan 22, 2018
• Director / officer changeNov 9, 2017
• Results of operationsNov 1, 2017
• Director / officer changeOct 20, 2017
• Entered a material agreement · Unregistered equity saleSep 22, 2017

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.